title: [The potential thrombolysis under selective infusion of the autologous plasmin (AP) solution].
abstract: The lytic therapy using Urokinase (UK) as well as Streptokinase (SK) has a significant risk of complications such as systemic bleeding. We aimed to develop the autologous plasmin (AP) solution as a potential lytic agent and to evaluate its lytic efficacy. Method; The AP solution was aseptically prepared by adding UK to autologous plasma separated by centrifugation (at 4 degrees C, 3,000 rpm, 10 min). The induced plasmin activity of the AP solution was measured by plasminogen-free fibrin plate method and spectrophotometric method with substrate S-2251. In vitro study, we made a fibrin clot by adding CaCl2 (1/40 mole, 0.2 ml) to autologous plasma (0.2 ml). The clot weight was measured before and after incubation for 60 min at 37 degrees C to estimate the lytic effects of the AP solution and the UK solution. In animal study, femoral artery of anesthetized mongrel dogs (n = 20) was narrowed by ligation (1 mm in diameter) and the fibrin clot was embolized into this portion. AP (n = 8), UK (n = 6) or saline (n = 6) was selectively injected for 3 min into the arterial lumen, after the temporary flow obstruction was completed by inflation of balloon tip catheter located proximal to the embolized site of the artery. Lytic effects on the embolized fibrin clot were sequentially observed by the extra-vascular ultrasound flow meter (equipped with pencil probe) for 60 min. For this study, the AP solution was prepared by adding dose of 12,000 IU/ml of UK. The same dose of the UK solution was also used as a control.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Mizutani
mesh_terms: D000818:Animals; D004285:Dogs; D005341:Fibrinolysin / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D013927:Thrombosis / Q000628:therapy; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
chemical_list: D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator